VIPR Discovery Rewrites CRISPR Origin Story With Ancient Viral DNA Targeting System

For billions of years, bacteria have carried a natural immune system that eventually became one of the most powerful tools in modern biology. CRISPR existed in bacteria long before scientists began using it, and across that vast span of time it acted as a defense mechanism against viruses, storing fragments of past invaders and using them to recognize and disable the same threats again. The gene-editing technology that grew out of that bacterial machinery now underpins laboratory research, agricultural products and a growing list of experimental medicines.

That origin story has always pointed in one direction: bacteria built CRISPR, and scientists borrowed it. Research published on September 17, 2026 by the lab of Nobel laureate Jennifer Doudna at the Innovative Genomics Institute at UC Berkeley now suggests the story runs much further back, and possibly the other way around. In two connected papers in the journal Science, the team describes an ancient progenitor of CRISPR that had been overlooked because it uses a never-before-seen coding system to find and bind DNA.

The newly discovered system is called VIPR, short for Viral Interference Programmable Repeat. It likely predates CRISPR and was found in viruses rather than in bacteria. The result rewrites the origin story: bacteria appear to have stolen a weapon made by viruses to fight other viruses.

The search that produced the finding ignored sequence and focused on shape, then used a genomic language model to flag a repeating pattern that nobody had recognized as meaningful. What emerged was a compact, RNA-guided DNA recognition system that reads its targets in a gapped, skipping rhythm rather than the continuous stretch that defines CRISPR, and that unwinds DNA with a protein-driven triplex instead of the base-pairing loop familiar from CRISPR biology.

Key Facts

The Innovative Genomics Institute reported on September 17, 2026 that the work was led by Nobel laureate Jennifer A. Doudna and that the two connected papers appeared that day in Science, published by AAAS. The system is named VIPR, for Viral Interference Programmable Repeat, and the researchers describe it as an ancient progenitor of CRISPR. The organizations tied to the research include the Innovative Genomics Institute, the University of California, Berkeley, the Howard Hughes Medical Institute and the Doudna Lab.

Peter Yoon and Kenneth Loi in the Doudna lab used an AI-assisted structural approach to search through roughly 2.3 million structures for proteins related to early CRISPR systems, turning up a few hundred candidates. One protein had the same shape as CRISPR proteins but was never found next to CRISPR RNAs. As Doudna put it, if you want to find something truly ancient, you need to look for something with a particular shape, not a particular sequence.

With a genomic language model, the team spotted a pattern: three bases were almost always GGT at high probability, repeating like beads on a string, with variable bases in between. Those alternating GGY and NN motifs define the VIPR RNAs. Phys.org reported on September 18, 2026 that the system uses an unusual skip-one code in which the guide RNA reads two DNA letters, skips one, then reads the next two, while a CRISPR guide matches its target in one continuous stretch.

Structural work by Terry Zhang and Trevor Docter showed that VIPR assembles from multiple proteins along its RNA and uses a protein-driven, three-stranded RNA-DNA-DNA triplex to pry open DNA. Cryo-electron microscopy showed VIPR proteins assembling into a helical filament along the RNA and skipping every third DNA base. The authors write that rather than invading the duplex through RNA strand exchange, VIPR systems use protein-driven triplex formation.

The team tested whether VIPR could bind DNA, silence a fluorescent reporter gene and block phage infection in E. coli. It could, and it could be reprogrammed to silence selected genes and protect bacteria from an invading phage. Science reported on September 17, 2026 that VIPR RNAs comprise alternating GGY/NN motifs that recognize double-stranded DNA through a noncontiguous, gapped code in which the variable NN dinucleotides collectively specify a gapped target sequence. The papers carry the DOIs 10.1126/science.aei0498 and 10.1126/science.aei3472, and they are accompanied by a Perspective from Jack P. K. Bravo titled A viral origin for RNA-guided immunity, DOI 10.1126/science.ael0758.

Analysis

The evolutionary implications reach deep. Class 1 CRISPR systems, thought to have evolved first, are defined by repeat-associated mysterious proteins known as RAMPs, among the most ancient features of CRISPR-Cas and proposed to date back to the last universal common ancestor, roughly 4 billion years ago. Phys.org reported on September 18, 2026 that the team traced where RAMPs came from using a structure-based approach and identified VIPR, an RNA-binding protein found in bacterial and viral genomes alongside a small noncoding RNA called vrRNA that acts as the guide.

Natural VIPR targets frequently occurred in rival bacteriophages, which points to an ancient arms race between viruses competing for control inside bacteria. Under that model, VIPR likely arose as a way for viruses to inactivate each other. The researchers propose that bacteria may then have co-opted VIPR systems from invading viruses and adapted them for host defense, eventually evolving into CRISPR. That link is strongly supported but currently lacks direct evidence.

The New York Times reported on September 17, 2026 that VIPR appears capable of targeting a wider range of genetic sequences, which would allow scientists to modify a larger portion of the genome, and that VIPR molecules are smaller than CRISPR components, making them potentially easier to deliver into cells, which is a major hurdle in developing gene-editing therapies. The same report notes that while CRISPR proteins cut through genes to disable them, VIPR proteins wrap around genes to achieve the same silencing effect.

What this really means is that the most advanced gene editors in the laboratory may be refinements of a much older biological invention, one that viruses were deploying long before bacteria turned a related system into CRISPR. The gapped code and the triplex mechanism are not incremental tweaks to a known design. They represent a different way of reading and holding DNA, and they arrived from an unexpected direction, from the very viruses that CRISPR was built to fight.

Why It Matters

The authors describe VIPR systems as the most minimal and potentially versatile platforms for RNA-guided DNA recognition encountered so far. They suggest that synthetic VIPR fusions could be used for genome editing, for DNA locus imaging and for epigenetic modification, which would place the system alongside CRISPR in the toolkits of laboratories that manipulate genomes.

The New York Times reported on September 17, 2026 that if further research confirms its effectiveness and safety, VIPR could open new possibilities for treating genetic diseases and advance gene therapy beyond current CRISPR-based approaches. The prospect of smaller editing molecules matters because delivery remains one of the hardest problems in translating gene editing into medicine.

Just as important is what the discovery says about where else useful systems might be hiding. The search covered roughly 2.3 million structures and still required a language model to reveal the repeating GGT pattern. Because VIPR was invisible to conventional sequence-based searches, other ancient systems may likewise be sitting in plain sight, defined by geometry rather than by the letters of their genetic code.

Next Up

The immediate next step is confirming the evolutionary handoff. The proposal that bacteria co-opted VIPR from viruses and turned it into CRISPR is strongly supported but currently lacks direct evidence, and that gap is the clearest target for follow-up work. Researchers will also want to establish whether VIPR can be engineered for use in human cells, where delivery and safety questions look very different from those in E. coli.

Beyond that, the Doudna lab and other groups are likely to keep mining structural databases for shape-matched relatives of ancient CRISPR proteins, and to test whether synthetic VIPR fusions can perform genome editing, DNA locus imaging and epigenetic modification as the authors propose. The two papers, published in Science on September 17, 2026, along with the accompanying Perspective, set that agenda.